DOCSLIB.ORG

Correlation of in Vitro Sulfonamide Resistance of the Gonococcus with Results of Sulfonamide Therapy*T CHARLES M

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Correlation of in Vitro Sulfonamide Resistance of the Gonococcus with Results of Sulfonamide Therapy*T CHARLES M Mar., 1944 Correlation of in vitro Sulfonamide Resistance of the Gonococcus with Results of Sulfonamide Therapy*t CHARLES M. CARPENTER, M.D., F.A.P.H.A., AND HELEN ACKERMAN University of Rochester, School of Medicine and Dentistry, Rochester, N. Ir. AND MILLARD E. WINCHESTER, M.D., F.A.P.H.A., AND JANE WHITTLE Glynn County Board of Health, Brunswick, Ga. PREVIOUS studies have demon- efficacy of sulfathiazole in patients with strated that in vitro the gonococcus gonococcal infection in New York City, acquires resistance to gradually in- and the susceptibility of the patient's creased concentrations of sulfanilamnide, strain of gonococcus to the drug in vitro. sulfapyridine, sulfathiazole, and sulfa- The present report records the results diazine.l1 It has been shown, further- of treatment with sulfathiazole on 105 more, that induced resistance of an patients with gonococcal infection and organism to one sulfonamide compound the in vitro behavior to sulfanilamide usually increases resistance to other and sulfathiazole of the strains of the derivatives of sulfanilamide.385 These gonococcus isolated from those patients. observations, together with an apparent This study was carried out at the decrease in the therapeutic efficacy of Glynn County Board of Health, sulfonamides in gonorrhea, suggested the Brunswick, Ga. investigation of a possible correlation between the laboratory and clinical MATERIALS AND METHODS findings. Information as to the preva- Patients with symptoms of uncom- lence of sulfonamide resistant strains of plicated urethritis of cervicitis reporting the gonococcus in a community follow- at the venereal disease clinic were ex- ing the widespread use of sulfonamides amined for evidence of gonococcal in- would in addition provide data of epi- fection. The film and cultural methods demiologic significance. Cohn and were used to verify the diagnosis of the Seijo 6 have recently reported a direct disease. Those from whom the gono- relationship between the therapeutic coccus was isolated were treated with a single course of therapy consisting of * Presented before the Epidemiology Section of 20 gm. of sulfathiazole administered in the American Public Health Association at the one of the two following manners: 3 Seventy-second Annual Meeting in New York, N. Y., October 14, 1943. gm. daily for 6 days and 2 gm. on the t This study was carried out in cobperation with 7th day or 4 gm. daily for 5 days. In the. Division of Venereal Diseases, U, S. Public Health Service, Washington, D. C. a few instances sulfapyrazine was sub- [2501 Vol. 34 SULFOlNAMIDE THERAPY 251 stituted for sulfathiazole. The patients Five ml. of medium in test tubes were returned to the clinic for examination inoculated with 0.1 ml. of a 24 hour once a week for at least 3 weeks, and Douglas's broth culture of the strain at each visit films and cultures were to be tested. A tube of blood broth again taken. A series of three negative without drug was also inoculated to bacteriologic examinations together with serve as a control. After 48 hours of the absence of clinical evidence of dis- incubation at 370 C. subcultures were ease comprised the criteria of cure. made to " chocolate " agar plates which Thus, patients responding to one course were similarly incubated, and the of therapy were considered " cured," presence or absence of growth was and those requiring additional treatment recorded. When growth occurred in any were designated " failures." The 105 tube containing drug, the strain was patients included in this study were designated " resistant." If no growth classified according to race and sex as was detected, the strain was considered follows: Negro, 79; white, 26. The "nonresistant." The minimal concen- Negroes comprised 54 males and 25 trations of 5 mg. per cent and 1 mg. females; the white patients, 13 males per cent of sulfanilamide and sulfa- and 13 females. Included in this group thiazole, respectively, were selected be- were only those patients with no history cause they were significantly higher of previous treatment with sulfonamide than the concentrations which were compounds. bactericidal for strains of the gono- The strain of gonococcus isolated coccus isolated from patients readily from each patient before treatment was cured with a single course of sulfona- tested in vitro for growth in blood-broth mide therapy. media containing sulfanilamide and sulfathiazole. As a rule, the tests were RESULTS carried out as soon as possible after iso- Of the 105 selected patients with lation, the strains examined for the most gonococcal infection from whom Neis- part being between the 5th and 10th seria gonorrhoeae was isolated prior to generations. In addition to the 105 sulfonamide therapy, 88, or 84 per cent, strains of the gonococcus recovered' were " cured " with one course of 20 from this group of patients, similar gm. of either sulfathiazole or sulfa- tests were made on 109 strains isolated pyrazine. The remaining 17, or 16 per in this same community. The observa- cent, failed to be cured with the same tion period of the study extended from amount of drug. May 1, 1942, to August 1, 1943. Seventy-seven strains of the gono- The medium was prepared in the coccus, 87.5 per cent, isolated from the following manner. Sulfanilamide to 88 patients designated as " cured ' yield final concentrations of 5, 10, 20, failed to grow in vitro in any of the and 40 mg. per cent was added to concentrations, 5, 10, 20, and 40 mg. Douglas's broth containing 0.05 per per cent sulfanilamide or in concentra- cent each of sodium phosphate and tions of 1, 2, 5, and 10 mg. per cent sodium nitrate. After sterilization in sulfathiazole. The remaining 11 strains, the autoclave at 121° C. for 10 min- 12.5 per cent, on the other hand, re- utes, 5 ml. of defibrinated lapine blood sisted the action of one or both drugs were added to each 100 ml. of the in vitro. medium. The sulfathiazole broth was Thirteen strains of the gonococcus, prepared in a similar manner except 76.5 per cent, recovered from 17 pa- that concentrations of 1, 2, 5, and 10 tients that failed to be cured likewise mg. per cent of the drug were employed. remained viable when exposed to the 252 AMERICAN JOURNAL OF PUBLIC HEALTH Mar., 1944 TABLE 1 Correlation of Effect of Sulfonamides on Neisseria gonorrhoeae in Vitro with Sulfonamide Therapy in 105 Patients Resistance to Sulfonamides Clinical Results with Sulfonamide Therapy of Strains of Gonococcus - - -- Isolated before Treatment Cured * Uncured -- No. of No. of No. of Strain Strains Per cent Patients Per cent Patients Per cent " Nonresistant " 81 77 77 95 4 5 " Resistant " 24 23 1 1 46 13 54 Total 105 100 88 84 17 .16 * Criteria of cure consisted of three negative bacteriologic examinations at weekly intervals together with the absence of clinical evidence of gonorrhea. above concentrations of sulfanilamide *ing the first 6 months of the study were and sulfathiazole in vitro, while 4 " resistant," whereas observations made strains, 23.5 per cent, did not survive during the last 3 months showed that the action of the drugs. 59.3 per cent of all strains examined A correlation between the curative. were " resistant " (Table 2). TABLE 2 Trend of Prevalence of in Vitro Sulfonamide Resistance of the Gonococcus in Br-unswick, Ga. Cultures Cultures "Nonresistant" "Resistant" Cultures to Sulfonamides to Sulfonamides "Resistant" Time Intervals Tested in Vitro in Vitro Cultures No. No. No. Per cent May, 1942-October, 1942 46 39 7 15.2 November, 1942-January, 1943 45 33 12 26.7 February, 1943-April, 1943 69 46 23 33.3 May, 1943-July, 1943 54 22 32 59.3 Total 214 140 74 34.-6 effect of the drugs in vivo and the re- DISCUSSION sistance of the specific organism in vitro Cohn and Seijo 6 working with 107 showed that of 81 patients infected strains of the gonococcus isolated from with " nonresistant " strains, 77, 95 per 101 patients in New York City have cent, were "cured," but that of 24 reported that 100 per cent of the pa- patients infected with "resistant" tients with " nonresistant " strains were strains, only 11, 46 per cent, were cured, but only 18 per cent of the pa- " cured " with an equivalent amount of tients with " resistant " strains re- the compound (Table 1). tovered. In our study, 95 per- cent of Of a total of 214 strains of the gono- the patients with " nonresistant " strains coccus isolated prior to treatment at responded favorably to sulfonamide Brunswick, Ga., during a 15 montb therapy as well as 46 per cent of the period from May 1, 1942, to August 1, patients with " resistant " strains. Thus 1943, and tested for sulfonamide re- in the group reported by Cohn and Seijo, sistance, 74, or 34.6 per cent, were only 3 of 17 patients with " resistant " " resistant " to sulfanilamide and sulfa- strains of the gonococcus were cured, thiazole in vitro. Of greater signifi- whereas in our group, 11 of 24 patients cance, however, is the finding that only with " resistant " strains recovered. A 15.2 per cent of these strains tested dur- valid comparison of the results obtained Vol.34 SULFONAMIDE THERAPY 253 in the two studies cannot be made be- of the gonococcus known to have been cause each patient of Cohn and Seijo re- exposed to sulfonamides. ceived during the first course of therapy Routine tests for the sulfonamide only a total of 14 gm. of drug. Our resistance of a strain of gonococcus in patients, on the other hand, were given vitro are as yet impractical because of a total of 20 gm. each. the time and expense involved.
Load more

Recommended publications
  • Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications
    International Journal of Molecular Sciences Review Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications Daniel Fernández-Villa 1, Maria Rosa Aguilar 1,2 and Luis Rojo 1,2,* 1 Instituto de Ciencia y Tecnología de Polímeros, Consejo Superior de Investigaciones Científicas, CSIC, 28006 Madrid, Spain; [email protected] (D.F.-V.); [email protected] (M.R.A.) 2 Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, 28029 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-915-622-900 Received: 18 September 2019; Accepted: 7 October 2019; Published: 9 October 2019 Abstract: Bacterial, protozoan and other microbial infections share an accelerated metabolic rate. In order to ensure a proper functioning of cell replication and proteins and nucleic acids synthesis processes, folate metabolism rate is also increased in these cases. For this reason, folic acid antagonists have been used since their discovery to treat different kinds of microbial infections, taking advantage of this metabolic difference when compared with human cells. However, resistances to these compounds have emerged since then and only combined therapies are currently used in clinic. In addition, some of these compounds have been found to have an immunomodulatory behavior that allows clinicians using them as anti-inflammatory or immunosuppressive drugs. Therefore, the aim of this review is to provide an updated state-of-the-art on the use of antifolates as antibacterial and immunomodulating agents in the clinical setting, as well as to present their action mechanisms and currently investigated biomedical applications. Keywords: folic acid antagonists; antifolates; antibiotics; antibacterials; immunomodulation; sulfonamides; antimalarial 1.
    [Show full text]
  • The Local Use of the Sulfonamide Drugs
    THE LOCAL USE OF THE SULFONAMIDE DRUGS GEORGE CRILE Jr., M.D. Since the introduction of sulfanilamide and its derivatives, the reliance upon chemotherapy for the control of acute surgical infections has temporarily overshadowed the importance of sound surgical princi- ples and often has resulted in the administration of inefficient or inade- quate treatment. Too often, the physician fails to recognize the limita- tions of chemotherapy and vainly attempts to control the infection well beyond the optimum time for surgical intervention. Chemotherapy is very effective in controlling infections from hemo- lytic streptococcus; is moderately effective in controlling staphylococcic infections; but is of slight value when administered systemically in patients infected with the nonhemolytic streptococcus or colon bacillus. However, even in infections caused by the hemolytic streptococcus or the staphylococcus, sulfanilamide and sulfathiazole cannot replace surgery after suppuration has taken place and mechanical drainage of an abscess is required. It is in the treatment of lymphangitis and cellulitis, not in the treatment of abscesses, that chemotherapy has been of the greatest value. The work of Lockwood1 and others has indicated that the products of proteolysis in vitro interfere with the bacteriostatic and bacteriocidal powers of sulfanilamide. The presence of similar substances in undrained abscess cavities probably interferes with the destruction of the organ- isms by chemotherapy. Accordingly, the sulfonamide drugs should supplement rather than replace early and adequate surgical drainage, especially in the presence of suppuration. The local application of the sulfonamide drugs is based upon the principle that the local concentration of the drug in the tissues is ten to twenty times as high as that which can be obtained by any method of systemic administration.
    [Show full text]
  • Milk and Dairy Beef Drug Residue Prevention
    Milk and Dairy Beef Drug Residue Prevention Producer Manual of Best Management Practices 2014 Connecting Cows, Cooperatives, Capitol Hill, and Consumers www.nmpf.org email: [email protected] National Milk Producers Federation (“NMPF”) does not endorse any of the veterinary drugs or tests identified on the lists in this manual. The lists of veterinary drugs and tests are provided only to inform producers what products may be available, and the producer is responsible for determining whether to use any of the veterinary drugs or tests. All information regarding the veterinary drugs or tests was obtained from the products’ manufacturers or sponsors, and NMPF has made no further attempt to validate or corroborate any of that information. NMPF urges producers to consult with their veterinarians before using any veterinary drug or test, including any of the products identified on the lists in this manual. In the event that there might be any injury, damage, loss or penalty that results from the use of these products, the manufacturer of the product, or the producer using the product, shall be responsible. NMPF is not responsible for, and shall have no liability for, any injury, damage, loss or penalty. ©2014 National Milk Producers Federation Cover photo courtesy of DMI FOREWORD The goal of our nation’s dairy farmers is to produce the best tasting and most wholesome milk possible. Our consumers demand the best from us and we meet the needs of our consumers every day. Day in and day out, we provide the best in animal husbandry and animal care practices for our animals.
    [Show full text]
  • Xifaxan® (Rifaximin)
    Wednesday, October 14, 2015 4 p.m. Oklahoma Health Care Authority 4345 N. Lincoln Blvd. Oklahoma City, OK 73105 The University of Oklahoma Health Sciences Center COLLEGE OF PHARMACY PHARMACY MANAGEMENT CONSULTANTS MEMORANDUM TO: Drug Utilization Review Board Members FROM: Bethany Holderread, Pharm.D. SUBJECT: Packet Contents for Board Meeting – October 14, 2015 DATE: October 1, 2015 NOTE: The DUR Board will meet at 4:00 p.m. The meeting will be held at 4345 N Lincoln Blvd. Enclosed are the following items related to the October meeting. Material is arranged in order of the agenda. Call to Order Public Comment Forum Action Item – Approval of DUR Board Meeting Minutes – Appendix A Action Item – Vote on 2016 Meeting Dates – Appendix B Update on Medication Coverage Authorization Unit/Bowel Preparation Medication Post-Educational Mailing – Appendix C Action Item – Vote to Prior Authorize Tykerb® (Lapatinib), Halaven® (Eribulin), Ixempra® (Ixabepilone), Kadcyla® (Ado-Trastuzumab), Afinitor® (Everolimus), & Perjeta® (Pertuzumab) – Appendix D Action Item – Vote to Prior Authorize Orkambi™ (Lumacaftor/Ivacaftor) – Appendix E Action Item – Vote to Prior Authorize Savaysa® (Edoxaban) – Appendix F Action Item – Vote to Prior Authorize Epanova® (Omega-3-Carboxylic Acids), Praluent® (Alirocumab), & Repatha™ (Evolocumab) – Appendix G Annual Review of Constipation and Diarrhea Medications and 30-Day Notice to Prior Authorize Movantik™ (Naloxegol), Viberzi™ (Eluxadoline), & Xifaxan® (Rifaximin) – Appendix H 30-Day Notice to Prior Authorize Daraprim® (Pyrimethamine) – Appendix I Annual Review of Allergy Immunotherapies and 30-Day Notice to Prior Authorize Oralair® (Sweet Vernal, Orchard, Perennial Rye, Timothy, & Kentucky Blue Grass Mixed Pollens Allergen Extract) – Appendix J Annual Review of Non-Steroidal Anti-Inflammatory Drugs and 30-Day Notice to Prior Authorize Dyloject™ (Diclofenac Sodium) – Appendix K ORI-4403 • P.O.
    [Show full text]
  • Chloroquinoxaline Sulfonamide (NSC 339004) Is a Topoisomerase II␣/␤ Poison1
    [CANCER RESEARCH 60, 5937–5940, November 1, 2000] Advances in Brief Chloroquinoxaline Sulfonamide (NSC 339004) Is a Topoisomerase II␣/␤ Poison1 Hanlin Gao, Edith F. Yamasaki, Kenneth K. Chan, Linus L. Shen, and Robert M. Snapka2 Departments of Radiology [H. G., E. F. Y., R. M. S.]; Molecular Virology, Immunology and Medical Genetics [H. G., R. M. S.]; College of Medicine [H. G., E. F. Y., R. M. S., K. K. C.]; and College of Pharmacy [K. K. C.], Ohio State University, Columbus, Ohio 43210, and Abbott Laboratories, Abbott Park, Illinois 60064 [L. L. S.] Abstract Drugs and Enzymes. CQS (NSC 339004) was provided by Dr. R. Shoe- maker, National Cancer Institute. VM-26 (teniposide, NSC 122819) was Chloroquinoxaline sulfonamide (chlorosulfaquinoxaline, CQS, NSC obtained from the National Cancer Institute Division of Cancer Treatment, 339004) is active against murine and human solid tumors. On the basis of Natural Products Branch. DMSO was the solvent for all drug stocks. Purified ␤ its structural similarity to the topoisomerase II -specific drug XK469, human topoisomerase II␣ was from TopoGen (Columbus, OH) and LLS ␣ CQS was tested and found to be both a topoisomerase-II and a topoi- (Abbott Laboratories, Abbott Park, IL). Purified topoisomerase II␤ was a ␤ somerase-II poison. Topoisomerase II poisoning by CQS is essentially gift of Dr. Caroline Austin (University of Newcastle, Newcastle upon Tyne, undetectable in assays using the common protein denaturant SDS, but United Kingdom). easily detectable with strong chaotropic protein denaturants. The finding Filter Assay for in Vitro Topoisomerase-DNA Cross-links. The GF/C that detection of topoisomerase poisoning can be so dependent on the filter assay for protein-SV40 DNA cross-links is used to measure topoisomer- protein denaturant used in the assay has implications for drug discovery ase poisoning in vitro with purified enzymes and DNA substrates (9).
    [Show full text]
  • Belgian Veterinary Surveillance of Antibacterial Consumption
    Belgian Veterinary Surveillance of Antibacterial Consumption National consumption report 2013 1 Summary This fifth BelVetSAC report, covers the results of the data collection on veterinary antibacterial consumption in Belgium in the year 2013. Data consist of all veterinary antibacterials sold to a veterinarian or pharmacist in Belgium and of antibacterial premixes incorporated in medicated feed intended to be used in Belgium for the year 2013. It includes thus consumption data for farm animals as well as companion animals. The denominator for animal production was the biomass (in kg) calculated as the sum of the amount of beef, pork and poultry meat produced in 2013, plus the number of dairy cattle present in Belgium times 500 kg of metabolic weight per head. As the usage data are concerned, this report shows for the second year in a row a decrease in the total consumption of antibacterial compounds in veterinary medicine of -6,6% between 2012 and 2013. Due to the relative stable animal production (expressed in biomass -0,3%) the decrease expressed in mg/kg biomass is -6,3%. When using 2011 as a reference, a reduction of -12,7% (expressed in mg/kg biomass) was achieved between 2011 and 2013, distributed over a reduction of -13,3% in antibacterial pharmaceuticals and -10,2% in antibacterial premixes. When looking more in detail to the different types of antibacterials used, it is observed that the penicillines (31,1%), sulphonamides (28,7%), and tetracyclines (24,1%) remain the three most used antibacterial classes. This year a substantial decrease in sulphonamide plus trimethoprim use and a limited decrease in penicillin and tetracycline use was observed.
    [Show full text]
  • Tetracycline and Sulfonamide Antibiotics in Soils: Presence, Fate and Environmental Risks
    processes Review Tetracycline and Sulfonamide Antibiotics in Soils: Presence, Fate and Environmental Risks Manuel Conde-Cid 1, Avelino Núñez-Delgado 2 , María José Fernández-Sanjurjo 2 , Esperanza Álvarez-Rodríguez 2, David Fernández-Calviño 1,* and Manuel Arias-Estévez 1 1 Soil Science and Agricultural Chemistry, Faculty Sciences, University Vigo, 32004 Ourense, Spain; [email protected] (M.C.-C.); [email protected] (M.A.-E.) 2 Department Soil Science and Agricultural Chemistry, Engineering Polytechnic School, University Santiago de Compostela, 27002 Lugo, Spain; [email protected] (A.N.-D.); [email protected] (M.J.F.-S.); [email protected] (E.Á.-R.) * Correspondence: [email protected] Received: 30 October 2020; Accepted: 13 November 2020; Published: 17 November 2020 Abstract: Veterinary antibiotics are widely used worldwide to treat and prevent infectious diseases, as well as (in countries where allowed) to promote growth and improve feeding efficiency of food-producing animals in livestock activities. Among the different antibiotic classes, tetracyclines and sulfonamides are two of the most used for veterinary proposals. Due to the fact that these compounds are poorly absorbed in the gut of animals, a significant proportion (up to ~90%) of them are excreted unchanged, thus reaching the environment mainly through the application of manures and slurries as fertilizers in agricultural fields. Once in the soil, antibiotics are subjected to a series of physicochemical and biological processes, which depend both on the antibiotic nature and soil characteristics. Adsorption/desorption to soil particles and degradation are the main processes that will affect the persistence, bioavailability, and environmental fate of these pollutants, thus determining their potential impacts and risks on human and ecological health.
    [Show full text]
  • Antimicrobial and Anticancer Activity of Some Novel Fluorinated
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Springer - Publisher Connector Ghorab et al. Chemistry Central Journal (2017) 11:32 DOI 10.1186/s13065-017-0258-4 RESEARCH ARTICLE Open Access Antimicrobial and anticancer activity of some novel fuorinated thiourea derivatives carrying sulfonamide moieties: synthesis, biological evaluation and molecular docking Mostafa M. Ghorab1,2*, Mansour S. Alsaid1, Mohamed S. A. El‑Gaby3*, Mahmoud M. Elaasser4 and Yassin M. Nissan5 Abstract Background: Various thiourea derivatives have been used as starting materials for compounds with better biological activities. Molecular modeling tools are used to explore their mechanism of action. Results: A new series of thioureas were synthesized. Fluorinated pyridine derivative 4a showed the highest anti‑ microbial activity (with MIC values ranged from 1.95 to 15.63 µg/mL). Interestingly, thiadiazole derivative 4c and coumarin derivative 4d exhibited selective antibacterial activities against Gram positive bacteria. Fluorinated pyridine derivative 4a was the most active against HepG2 with IC50 value of 4.8 μg/mL. Molecular docking was performed on the active site of MK-2 with good results. Conclusion: Novel compounds were obtained with good anticancer and antibacterial activity especially fuorinated pyridine derivative 4a and molecular docking study suggest good activity as mitogen activated protein kinase-2 inhibitor. Keywords: Isothiocyanate, Sulfonamide, Fluorinated thiourea, Antimicrobial and anticancer activity Background the increased hydrophobicity, and (v) the second small- Fluorinated compounds are intriguing for the develop- est atomic radius of the fuorine atom. Tese factors are ment of pharmaceuticals, agrochemicals, and materials, operative singly or sometimes cooperatively to afect the and thus, much efort has been exerted to develop more pharmacological properties of the fuorinated molecules general and efcient approaches for introducing fuorine [5].
    [Show full text]
  • 22-554 Microbiology Review(S)
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 22-554 MICROBIOLOGY REVIEW(S) MICROBIOLOGY REVIEW DIVISION OF SPECIAL PATHOGEN AND TRANSPLANT PRODUCTS NDA #: 21361 (S-011, SDN #100) REVIEWER : Anne Purfield and 22554 (S-06, SDN #1) CORRESPONDENCE DATE : 7-21-09; 6-24-09 CDER RECEIPT DATE : 7-22-09; 6-26-09 REVIEW ASSIGN DATE : 8-25-09 REVIEW COMPLETE DATE: 10-07-09 APPLICANT: Salix Pharmaceuticals, Inc. 1700 Perimeter Dr Morrisville, NC 27560 DRUG CATEGORY: Antibacterial INDICATION: Treatment of travelers’ diarrhea Treatment of hepatic encephalopathy (NDA #22554 under review in Division of Gastroenterology Products) DOSAGE FORM: Tablet for oral administration PRODUCT NAMES: a. PROPRIETARY: Xifaxan® b. NONPROPRIETARY: Rifaximin c. CHEMICAL: (2S,16Z,18E,20S,21S,22R,23R,24R,25S,26S,27S,28E)- 5,6,21,23,25-pentahydroxy-27-methoxy-2,4,11,16,20,22,24,26- octamethyl-2,7-(epoxypentadeca-[1,11,13]trienimino)benzofuro [4,5-e]pyrido[1,2-a]-benzimida-zole-1,15(2H)-dione,25-acetate STRUCTURAL FORMULA: Molecular weight: 785.879 Molecular formula: C43H51N3O11 SUPPORTING DOCUMENTS: NDA #22554, NDA #21361 Rifaximin 2 NDA #21361, #22554 Salix Pharmaceuticals, Inc. Table of Contents Page 1. Executive Summary …………………………………………………………………. 3 2. Introduction and Background ……………………………………………………… 4 3. Preclinical/Nonclinical Microbiology ………………………………………………. 4 3.1 Jiang et al., 2005………………………………………………………………… 4 3.2 Vosbeck et al., 1979…………………………………………………………….. 5 3.3 Debbia et al., 2008………………………………………………………………. 5 4. Clinical Microbiology ……………………………………………………………….. 8 4.1 Description of clinical studies ………………………………………………….... 8 4.1.1. DuPont et al., 1998 ...………………………………………………….. 8 4.1.2 DuPont et al., 2001 …………………………………………………….. 10 4.2 Interpretive Criteria …………………………………………………………... 14 5.
    [Show full text]
  • Common Antibiotics
    COMMON ANTIBIOTICS DANA BARTLETT, RN, BSN, MSN, MA Dana Bartlett is a professional nurse and author. His clinical experience includes 16 years of ICU and ER experience and over 20 years of as a poison control center information specialist. Dana has published numerous CE and journal articles, written NCLEX material, written textbook chapters, and done editing and reviewing for publishers such as Elsevire, Lippincott, and Thieme. He has written widely on the subject of toxicology and was recently named a contributing editor, toxicology section, for Critical Care Nurse journal. He is currently employed at the Connecticut Poison Control Center and is actively involved in lecturing and mentoring nurses, emergency medical residents and pharmacy students. ABSTRACT There are many antibiotics available in the United States to treat various forms of infection. Understanding the benefits and risks of antibiotic therapy, such as adverse effects associated with specific antibiotics, and the safe administration and monitoring of patients receiving antibiotics can appear daunting. However, issues of antibiotic therapy may be approached by knowing the adverse effects common to all antibiotics, those at risk of having adverse effects and the level of severity of adverse effects as well as any testing required for detection. The main classes of antibiotics and the specific antibiotics available in the U.S., in particular, the aminoglycoside, carbapenem, cephalosporin, glycopeptide, lincosamide, macrolide, penicillin, quinolone, sulfonamide, tetracycline,
    [Show full text]
  • Applications
    APPLICATIONS Zeshan Aqeel Senior Application Scientist A Screen of 22 Common Antibiotics that Demonstrates Zeshan loves to collect watches and the Back to the the Unique Reversed Phase Selectivity and Improved Future Trilogy. He has twin boys who drive him crazy! He Chromatographic Performance for Bases using a is an Apple Fanboy for life and ® he likes being in the lab more Kinetex PS C18 HPLC/UHPLC Column than anywhere else. Zeshan Aqeel, Jeff Layne, and Ryan Splitstone Phenomenex, Inc., 411 Madrid Ave, Torrance CA 90501 USA Overview Ciprofloxacin The Kinetex PS C18 is a USP classified L1 column, that provides Molecular Formula: C17H19FN3O3 both a unique polar/hydrophobic selectivity, and is 100 % aqueous Basic pKa: 8.77 stable. The column demonstrates enhanced selectivity and peak Acidic pKa: 5.56 shape for basic compounds under typical reversed phase condi- LogP: -0.86 tions. In addition, the solid support is a Kinetex core-shell (superfi- CH3 cially porous) particle morphology that provides ultra-high column + O S O 1 NH efficiency on any HPLC or UHPLC system. CH3 2 N N + O S O The mobile phase program chosen was a routine gradientNH of Acetonitrile with 0.1 % Formic Acid as the strong organic solvent2 and Water with 0.1 % Formic Acid as Nthe weak solvent.N The flow O F rate of 0.5 mL/min was used, and the column heater was set to ambient temperature (25 °C).O OH O F F OH Introduction OH O HO N In this application, 22 antibiotics were analyzed to demonstrate the F OH Kinetex PS C18 HPLC/UHPLC column’s unique multi-modal selec- F tivity and improved chromatographic performance for polar bases.
    [Show full text]
  • Design, Synthesis and Pharmacological Evaluation of Sulfanilamide-Ciprofloxacin Conjugates Utilizing Hybridization Approach As New Antibacterial Agents
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by International Institute for Science, Technology and Education (IISTE): E-Journals Journal of Natural Sciences Research www.iiste.org ISSN 2224-3186 (Paper) ISSN 2225-0921 (Online) Vol.5, No.4, 2015 Design, Synthesis and Pharmacological Evaluation of Sulfanilamide-Ciprofloxacin Conjugates Utilizing Hybridization Approach as New Antibacterial Agents Mohamed Hassan Mohammed 1 Monther Faisal Mahdi 2 Noor Hatef Naser 3 Sulaf Majeed Ali 4 1.Department of Pharmaceutical Chemistry, College of Pharmacy, University of Baghdad, Baghdad, Iraq 2.Department of Pharmaceutical Chemistry, College of Pharmacy, University of Al-Mustansiriyah, Baghdad, Iraq 3.Department of Pharmaceutical Chemistry, College of Pharmacy, University of Kufa,Najaf, Iraq 4.Ministry of Health, Directorate of General Health National Reference Laboratory E-Mail of Corresponding author :[email protected] Abstract A group of novel antibacterial agents (I-V) were designed and synthesized, by utilizing hybridization approach between ciprofloxacin and sulfanilamide, through metabolically stable linkers, to be acted by dual mode of actions. Ciprofloxacin acts by inhibition of topoisomerase enzyme, which is necessary for DNA replication, while sulfonamides act through inhibition of carbonic anhydrase enzyme, which is necessary for bacterial metabolic activity. Anti-tuberculosis activity of these compounds was evaluated on MDR Mycobacterium tuberculosis (resist to rifampicin and INH), in a dose equivalent to (10 mg/ 5 ml D.W.) of ciprofloxacin. Compounds II, III showed non-significant reduction in the number of bacterial colonies (bacterial growth) with respect to the effect of ciprofloxacin (standard), compound IV produce a significant reduction in the number of bacterial colonies in comparable to ciprofloxacin.
    [Show full text]